Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Data inconclusive based on available public sources regarding a publicly listed entity named Apotex Health Corp. trading under the ticker APTX.TO on the Toronto Stock Exchange. Publicly available records through major market data providers, Canadian securities databases, and widely referenced financial publications do not consistently identify an active issuer under that exact legal name and ticker combination.
Available public information does confirm the existence of Apotex Inc., a Canadian pharmaceutical company headquartered in Toronto that operates primarily in the generic pharmaceuticals and health products industry. Apotex Inc. is known for manufacturing generic medicines, over-the-counter products, and specialty pharmaceuticals for Canadian and international markets. However, public-source verification does not conclusively establish that Apotex Inc. is the same entity as “Apotex Health Corp.” or that it is publicly traded under APTX.TO.
Business Operations
Based on publicly available information related to Apotex Inc., the company’s operations historically centered on the development, manufacturing, licensing, and commercialization of generic pharmaceutical products and consumer health products. Revenue generation has primarily been tied to prescription generics, licensing arrangements, and international pharmaceutical distribution. The company has maintained manufacturing and research capabilities in Canada and has distributed products across multiple international jurisdictions.
Public records indicate that Apotex Inc. has operated through pharmaceutical manufacturing, regulatory affairs, and research and development functions, with products sold in markets including Canada, the United States, and other international regions. Data inconclusive based on available public sources regarding the current operating segments, audited financial structure, subsidiaries, or business-unit disclosures of “Apotex Health Corp.” specifically.
Strategic Position & Investments
Historically, Apotex Inc. has positioned itself as one of Canada’s largest generic drug manufacturers, competing on cost efficiency, product breadth, and regulatory approvals across multiple therapeutic categories. Strategic priorities publicly associated with the company have included expanding generic drug portfolios, increasing international market access, and investing in pharmaceutical manufacturing capabilities and product development.
Publicly available information also indicates involvement in specialty pharmaceuticals and consumer health categories, though detailed investment disclosures, acquisition history, and portfolio-company structures for “Apotex Health Corp.” specifically could not be independently verified through consistent public filings. Data inconclusive based on available public sources regarding major recent acquisitions, venture investments, or publicly disclosed emerging-technology initiatives tied directly to APTX.TO.
Geographic Footprint
Public information associated with Apotex Inc. identifies its headquarters in Toronto, Canada, with operational and commercial activities extending into North America, Europe, Asia, and certain emerging pharmaceutical markets. The company has historically exported pharmaceutical products internationally and maintained regulatory approvals in multiple jurisdictions.
The organization’s manufacturing and distribution footprint has reportedly included facilities and partnerships serving both domestic Canadian demand and export markets. However, detailed geographic revenue exposure, regional segment reporting, and current international operating structure for “Apotex Health Corp.” under the ticker APTX.TO could not be conclusively verified.
Leadership & Governance
Publicly available information connected to Apotex Inc. identifies the company as being founded by Barry Sherman and Honey Sherman, who played major roles in building the business into a significant Canadian pharmaceutical manufacturer. Following their deaths in 2017, leadership transitioned through a revised executive and governance structure.
Recent publicly referenced executives associated with Apotex Inc. include:
- Allan Oberman – Chairman
- Sandra Levy – President and Chief Executive Officer
- Jeff Watson – Chief Financial Officer
Data inconclusive based on available public sources regarding the current executive roster, board composition, and governance disclosures specifically for “Apotex Health Corp.” as a separately listed public company under APTX.TO.